ATCC 100 Years Logo Anniversary ATCC 100 Years Logo Anniversary Cart 0
  • Careers
  • Support

hTERT HME2

CRL-3543

hTERT HME2 are hTERT immortalized cells exhibiting epithelial morphology that were isolated from normal disease-free breast tissues of an adult female patient undergoing reduction mammoplasty surgery. hTERT HME2 cells may be used for drug development, high-throughput screening, and quality control.
Product category
Human cells
Organism
Homo sapiens, human
Cell type
epithelial-like cell
Morphology
Epithelial-like
Tissue
Breast
Disease
Normal
Product format
Frozen
Storage conditions
Vapor phase of liquid nitrogen
Buy Now
Price: $6,256.00 ea
Discounts may be available for our fellow nonprofit organizations. Login to see your price.

Generally ships within 1-3 business days

Documentation

ATCC determines the biosafety level of a material based on our risk assessment as guided by the current edition of Biosafety in Microbiological and Biomedical Laboratories (BMBL), U.S. Department of Health and Human Services. It is your responsibility to understand the hazards associated with the material per your organization’s policies and procedures as well as any other applicable regulations as enforced by your local or national agencies.

ATCC highly recommends that appropriate personal protective equipment is always used when handling vials. For cultures that require storage in liquid nitrogen, it is important to note that some vials may leak when submersed in liquid nitrogen and will slowly fill with liquid nitrogen. Upon thawing, the conversion of the liquid nitrogen back to its gas phase may result in the vial exploding or blowing off its cap with dangerous force creating flying debris. Unless necessary, ATCC recommends that these cultures be stored in the vapor phase of liquid nitrogen rather than submersed in liquid nitrogen.

Detailed product information

General

Specific applications
Drug development, 3D cell culture, high-throughput screening, cancer research

Characteristics

Cells per vial
≥ 1.0 x 106
Growth properties
Adherent
Gender
Female
Karyotype

46,XX (6 cells)
45,XX, der(10;15)(q10;q10)

Antigen expression
VDR, AR
Genes expressed
hTERT expression
Comments
This cell line was isolated from normal disease-free breast tissues of an adult female patient undergoing reduction mammoplasty surgery.

Handling information

Complete medium
The medium for this cell line is MEGM™ Mammary Epithelial Cell Growth Medium BulletKit™ (Lonza catalog #CC-3150). The medium includes MEBM™ Basal Medium + MEGM™ SingleQuots™ Supplements without GA-1000. To make the complete growth medium, follow the instructions provided by Lonza, excluding the GA-1000.
Temperature
37°C
Atmosphere
95% Air, 5% CO2
Handling procedure
To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C.  Storage at -70°C will result in loss of viability.

  1. Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water.  Thawing should be rapid (approximately 2 minutes).
  2. Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.
  3. Transfer the vial contents to a centrifuge tube containing 9.0 mL complete culture medium and spin at approximately 125 to 400 x g for 8 to 12 minutes.
  4. Carefully aspirate the supernatant and discard, leaving the cell pellet.
  5. Gently resuspend the cell pellet with the appropriate amounto of complete growth medium and transfer cell suspension into a vented T-75.
  6. Place the flask in a 37°C incubator with 5% CO2 .
Subculturing procedure

It is recommended to subculture at less than 90% confluence. Do not allow cultures to become over confluent.

Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes. 

  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA for Primary Cells (ATCC PCS-999-003) to flask and observe cells under an inverted microscope until the cell layer is dispersed (usually within 5 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 33°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of Trypsin Neutralizing Solution (ATCC PCS-999-004) and aspirate cells by gently pipetting.
  5. Centrifuge the cell suspension at approximately 150 to 400 x g for 8 to 12 minutes to remove dissociation agent.
  6. Resuspend the cell pellet in an appropriate amount of complete culture medium.
  7. Add appropriate aliquots of the cell suspension to new culture vessels.
    Cultures can be established between 2.0 x 104 and 4.0 x 104 viable cells/cm2.
  8. Incubate cultures at 37°C.
Interval: Maintain cultures at a cell concentration between 1.0 X 104 and 3.0 X 104 cell/cm2
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended
Medium Renewal: Every 2 to 3 days

Reagents for cryopreservation
Complete culture medium + 7.5% FBS (ATCC 30-2020) + 5% DMSO (ATCC 4-X)

Quality control specifications

Bacterial and fungal testing
Not detected
Mycoplasma contamination
Not detected
Virus testing
Not detected

History

Depositors
Tan A. Ince, MD, PhD
Chair, Department of Pathology
NewYork-Presbyterian Brooklyn Methodist Hospital
506 6th Street, Brooklyn, NY 11215
Department of Pathology, Room CP2006
 
Year of origin
2003

Legal disclaimers

Intended use
This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use.
Warranty

The product is provided 'AS IS' and the viability of ATCC® products is warranted for 30 days from the date of shipment, provided that the customer has stored and handled the product according to the information included on the product information sheet, website, and Certificate of Analysis. For living cultures, ATCC lists the media formulation and reagents that have been found to be effective for the product. While other unspecified media and reagents may also produce satisfactory results, a change in the ATCC and/or depositor-recommended protocols may affect the recovery, growth, and/or function of the product. If an alternative medium formulation or reagent is used, the ATCC warranty for viability is no longer valid.  Except as expressly set forth herein, no other warranties of any kind are provided, express or implied, including, but not limited to, any implied warranties of merchantability, fitness for a particular purpose, manufacture according to cGMP standards, typicality, safety, accuracy, and/or noninfringement.

Disclaimers

This product is intended for laboratory research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. Any proposed commercial use is prohibited without a license from ATCC.

While ATCC uses reasonable efforts to include accurate and up-to-date information on this product sheet, ATCC makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. ATCC does not warrant that such information has been confirmed to be accurate or complete and the customer bears the sole responsibility of confirming the accuracy and completeness of any such information.

This product is sent on the condition that the customer is responsible for and assumes all risk and responsibility in connection with the receipt, handling, storage, disposal, and use of the ATCC product including without limitation taking all appropriate safety and handling precautions to minimize health or environmental risk. As a condition of receiving the material, the customer agrees that any activity undertaken with the ATCC product and any progeny or modifications will be conducted in compliance with all applicable laws, regulations, and guidelines. This product is provided 'AS IS' with no representations or warranties whatsoever except as expressly set forth herein and in no event shall ATCC, its parents, subsidiaries, directors, officers, agents, employees, assigns, successors, and affiliates be liable for indirect, special, incidental, or consequential damages of any kind in connection with or arising out of the customer's use of the product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, ATCC is not liable for damages arising from the misidentification or misrepresentation of such materials.

Please see the material transfer agreement (MTA) for further details regarding the use of this product. The MTA is available at www.atcc.org.

Permits & Restrictions

Material Transfer Agreement Addendum for Screening Applications

For-profit organizations
For every order of this item, you must provide a signed Material Transfer Agreement Addendum for Screening Applications. We cannot ship this item until we receive this addendum. The person signing the addendum must have the full authority to execute legally binding agreements on behalf of your organization. For example, this person may be a technology transfer officer, legal officer, or corporate officer.

Email the signed addendum to [email protected] with a reference to both your account and sales order numbers. Once received, your addendum will be reviewed, and this item will be released for shipment if all requirements are met. Additional fees may apply if this product is being used for a screening use (ATCC ACS-2103F), and these fees will be applied after your order is confirmed. If you need assistance with your order, please contact our Customer Care team or your applicable distributor.

MORE INFORMATION ABOUT PERMITS AND RESTRICTIONS

Frequently Asked Questions

References

Curated Citations

Ince TA, Cancer Cell. 2007 Aug;12(2):160-70. doi: 10.1016/j.ccr.2007.06.013. PubMed: 17692807

Caslini, Corrado et al. HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells. Oncogene vol. 38,39 (2019): 6599-6614. doi:10.1038/s41388-019-0897-0, PubMed: 31375747

Fields, Evan et al. Predictive bioinformatics identifies novel regulators of proliferation in a cancer stem cell model. Stem cell research vol. 26 (2018): 1-7. doi:10.1016/j.scr.2017.11.009, PubMed: 29179130

O'Day, Elizabeth M et al. Cytidine monophosphate N-acetylneuraminic acid synthetase enhances invasion of human triple-negative breast cancer cells. OncoTargets and therapy vol. 11 6827-6838. 11 Oct. 2018, doi:10.2147/OTT.S177639, PubMed: 30349315

Chan, Stefanie et al. Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival. Molecular cancer therapeutics vol. 16,12 (2017): 2849-2861. doi:10.1158/1535-7163.MCT-17-0461, PubMed: 28878028

View All Curated Citations for this Product

For product-related inquiries and issues, contact Product Experience:

Message Us

Hours of Operation

Monday - Friday
9:00am - 5:00pm
US Eastern Time